

AVEO Pharma - PhIII, TIVO-1 Data and Reaction - No Surprise!

<https://marketpublishers.com/r/A8F043E0E86EN.html>

Date: January 2012

Pages: 3

Price: US\$ 90.00 (Single User License)

ID: A8F043E0E86EN

Abstracts

Data from TIVO-1, PhIII study (head-to-head study with ONXX's Nexavar) of Tivozanib (formerly AV-951, partnered with Astellas) in first-line Renal Cell Carcinoma (RCC) reiterate our belief that the drug is incapable to beat the drug of choice in 1st-line, PFE's Sutent. Safety profile was consistent with earlier study and concerns around safety may pose hurdles in the regulatory approval! With the current data showing marginal benefit vs. Nexavar, the future is not bright as it has to compete against Sutent, Nexavar (off-label), PFE's Torisel, Roche's Avastin, GSK's Votrient and PFE's Inlyta (axitinib, awaiting approval, PDUFA: Mar 13, 2012)! For more details, please read our report released on 4th January, 2012 on AVEO pharma titled "PhIII, TIVO-1 Data and Reaction - No Surprise!"

Contents

COMPANIES MENTIONED

AVEO PHARMA

I would like to order

Product name: AVEO Pharma - PhIII, TIVO-1 Data and Reaction - No Surprise!

Product link: <https://marketpublishers.com/r/A8F043E0E86EN.html>

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A8F043E0E86EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970